Spelling suggestions: "subject:"colitis ulcerative"" "subject:"colitis alcerative""
11 |
The therapeutic effects of cathelicidin-encoding Lactococcus lactis on murine ulcerative colitis. / CUHK electronic theses & dissertations collectionJanuary 2012 (has links)
潰瘍性結腸炎 (UC) 是一種原因不明的炎症性腸道疾病,治療原則是減輕炎症,但UC的病因有多種,一般消炎藥物如柳氮磺胺吡啶 (sulfasalazine) 等治療都是單靶向並有嚴重副作用,故副作用低、多靶向藥物是必要的。 / Cathelicidin 是一種抗菌抗炎的肽。事實上,鼠的 cathelicidin (mCRAMP) 直腸給藥能緩解小鼠 UC。為了提高療效及方便給藥,mCRAMP 編碼被導入乳酸乳球菌中。乳酸乳球菌是一種能抵抗胃酸的乳酸益生菌,因此口服亦能生產及傳送 cathelcidin 到大腸。 / 小鼠用含3% 葡聚醣硫酸鈉 (DSS) 的水7天以誘導UC。小鼠隨機分為十組,各接受每日一次的口服製劑:(1) 水,(2) DSS,(3, 4) DSS + 10¹° cfu 有或沒有 nisin 誘導的乳酸乳球菌,(5-8) DSS + 10⁸ 或 10¹° cfu有 (N4I) 或沒有 nisin 誘導的 mCRAMP 編碼乳酸乳球菌,(9) DSS + 0.5% 羧甲基纖維素鈉 (CMC-Na) 及 (10) DSS + 600 mg/kg懸浮於0.5% CMC-Na 的 sulfasalazine。 / 研究對 UC 預防效果時,小鼠同時接受 DSS 及治療。所有益生菌製劑中,只有 N4I 能降低中性粒細胞浸潤、脂質過氧化和炎症細胞因子表達,同時保護腸隱窩及黏膜分泌層結構,減少細胞凋亡及腸道菌群。相比之下,sulfasalazine 能抑制炎症但不能阻止結腸結構損傷。 / 進一步研究治療效果時,小鼠在炎症形成後接受四天治療。N4I 能促進結腸黏膜恢復,改善結腸和黏液分泌層的結構。這些作用可能通過刺激細胞增殖和抑制凋亡造成。相對地,sulfasalazine 對結腸組織重組沒有影響。 / 為了研究 mCRAMP 直接消炎作用,小鼠巨噬細胞 RAW 264.7 被脂磷壁酸和脂多醣刺激以模仿 UC 時細菌引起的炎症。mCRAMP 能減輕腫瘤壞死因子-α分泌及IκBα磷酸化並抑制核因子-κB (NF-κB) 活化,炎症酶如誘導型一氧化氮合酶和環氧合酶-2的表達也減少了。mCRAMP可能直接抑制細菌毒素與受體結合和/或直接抑制 NF-κB 產生消炎作用。 / 在研究 mCRAMP 修復黏膜的作用中,證實 mCRAMP 通過 G 蛋白偶聯受體依賴途徑和間接激活表皮生長因子受體、激活下游絲裂原活化蛋白激酶而促進細胞遷移、加速癒合。 / 總括而言,本研究首次顯示mCRAMP編碼乳酸乳球菌對 UC 有保護和治療作用,其抗炎、抗菌及促進黏膜修復作用來自乳酸乳球菌分泌的mCRAMP。多靶向的mCRAMP編碼乳酸乳球菌具有很大潛力,是一種比標準藥物 sulfasalazine 更好的治療結腸炎製劑。 / Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease (IBD). The mainstay of drug treatment is to relieve inflammation. However the aetiology of UC is multi-factorial while most of the anti-inflammatory drugs, such as sulfasalazine, aim at single target with severe side effects. Therefore, a multi-targeted drug with low systemic toxicity is warranted. / Cathelicidin, a host defense peptide, shows anti-microbial and anti-inflammatory effects. Indeed intra-rectal administration of mouse cathelicidin (mCRAMP) alleviated murine colitis. To improve therapeutic efficacy and reduce inconvenience of administration, Lactococcus lactis (L. lactis) was constructed to encode cathelicidin. L. lactis is a lactic acid probiotic which could resist gastric acid and be able to produce and deliver cathelicidin to the colon when given orally. / Murine colitis was induced by 3% dextran sulphate sodium (DSS) given in drinking water for 7 days. Mice were given intragastrically with the following preparations once daily: (1) water, (2) DSS, (3, 4) DSS + 10¹° cfu L. lactis with or without nisin induction, (5-8) DSS + 10⁸ or 10¹° cfu mCRAMP-encoding L. lactis with (N4I) or without nisin induction, (9) DSS + 0.5% sodium carboxymethylcellulose (CMC-Na) and (10) DSS + 600 mg/kg sulfasalazine suspended in 0.5 % CMC-Na. / To study the preventive effects, mice received the above treatments together with DSS administration. N4I but not the other probiotic preparations suppressed inflammation by reducing neutrophil infiltration, lipid peroxidation and inflammatory cytokines expressions. Crypt structure and mucus-secreting layer were conserved together with the reduction of apoptosis and intestinal microbiota. In contrast, sulfasalazine could only suppress inflammation but not the destruction of colonic structure. / To further examine the therapeutic effects, mice received treatments for 4 consecutive days after the inflammation formation. Similarly, only N4I promoted colonic mucosal recovery and preserved colon structure and mucus-secreting layer. These actions are likely mediated through cell proliferation stimulation and apoptosis suppression. Again, sulfasalazine had no effects on colon tissue reconstitution. / The direct anti-inflammatory action of mCRAMP was also studied. Mouse macrophage RAW 264.7 cells were stimulated by lipoteichoic acid and lipopolysaccharide to mimic bacteria-induced inflammation during UC. mCRAMP prevented tumour necrosis factor-α secretion and IκBα phosphorylation followed by nuclear factor-κB (NF-κB) suppression. The inflammatory enzymes including inducible nitric oxide synthase and cyclooxygenase-2 were also reduced. It was postulated that mCRAMP might directly interact with the bacterial toxins to reduce receptor complex binding and/or reduce NF-κB suppression in macrophages. / The repairing action of mCRAMP on mucosal damage was studied in mouse colon cells. mCRAMP incubation reduced the wound size by promoting cell migration through the G-protein coupled receptor and epidermal growth factor receptor transactivation followed by the mitogen-activated protein kinases activation. / In conclusion, the present study demonstrates for the first time the protective and therapeutic roles of mCRAMP-encoding L. lactis in UC. It was the mCRAMP secreted from the probiotic to produce both anti-inflammatory and anti-bacterial actions and further promote mucosal repair. mCRAMP-encoding L. lactis is a multi-targeted agent for IBD. It has a great potential to be a new therapeutic agent better than sulfasalazine for the treatment of UC. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Wong, Ching Man. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 227-250). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese. / Abstract --- p.i / Acknowledgement --- p.v / Table of Content --- p.vi / List of Abbreviations --- p.xiii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Ulcerative Colitis --- p.1 / Chapter 1.1.1 --- Overview --- p.1 / Chapter 1.1.2 --- Epidemiology --- p.2 / Chapter 1.1.3 --- Diagnosis --- p.2 / Chapter 1.1.3.1 --- Clinical Presentation --- p.2 / Chapter 1.1.3.2 --- Apparative Diagnostics --- p.3 / Chapter 1.1.3.3 --- Innovative Diagnostics in IBD --- p.4 / Chapter 1.1.4 --- Etiopathogenesis --- p.4 / Chapter 1.1.4.1 --- Genetic Predisposition --- p.4 / Chapter 1.1.4.2 --- Environmental Factors --- p.5 / Chapter 1.1.4.2.1 --- Life Style --- p.5 / Chapter 1.1.4.2.1.1 --- Smoking --- p.5 / Chapter 1.1.4.2.1.2 --- Diet --- p.6 / Chapter 1.1.4.2.1.3 --- Hygiene --- p.6 / Chapter 1.1.4.2.1.4 --- Psychological Stress --- p.6 / Chapter 1.1.4.2.1.5 --- Appendectomy --- p.7 / Chapter 1.1.4.2.2 --- Colonic Mucus --- p.7 / Chapter 1.1.4.2.3 --- Non-steroidal Anti-inflammatory Drugs (NSAIDs) --- p.7 / Chapter 1.1.4.3 --- Alteration of Intestinal Microbiota --- p.8 / Chapter 1.1.4.4 --- Immune Factors --- p.10 / Chapter 1.1.5 --- Existing Treatments --- p.10 / Chapter 1.1.5.1 --- 5-Aminosalicyclic Acid --- p.11 / Chapter 1.1.5.2 --- Corticosteroids --- p.12 / Chapter 1.1.5.3 --- Immunomodulators --- p.12 / Chapter 1.1.5.4 --- Surgical Management --- p.13 / Chapter 1.1.6 --- Emerging Treatments --- p.14 / Chapter 1.1.6.1 --- Antibiotics --- p.14 / Chapter 1.1.6.2 --- Probiotics --- p.14 / Chapter 1.1.6.3 --- Nicotine Patches --- p.14 / Chapter 1.1.6.4 --- Butyrate --- p.14 / Chapter 1.1.6.5 --- Biological Therapies --- p.15 / Chapter 1.1.7 --- Risk of Colorectal Cancer --- p.17 / Chapter 1.2 --- Cathelicidin --- p.17 / Chapter 1.2.1 --- Cathelicidin Family --- p.17 / Chapter 1.2.2 --- Actions and Possible Mechanisms --- p.19 / Chapter 1.2.3 --- Cathelicidin in Ulcerative Colitis --- p.20 / Chapter 1.3 --- Probiotics --- p.21 / Chapter 1.3.1 --- Lactic Acid Bacteria --- p.21 / Chapter 1.3.2 --- Definition of Probiotics --- p.22 / Chapter 1.3.3 --- Possible Mechanisms of Action of Probiotics --- p.23 / Chapter 1.3.3.1 --- Mucous Layer --- p.23 / Chapter 1.3.3.2 --- Host Cell Antimicrobial Peptides --- p.25 / Chapter 1.3.3.3 --- Probiotic Antimicrobial Factors --- p.25 / Chapter 1.3.3.4 --- Epithelial Adherence --- p.27 / Chapter 1.3.4 --- Recent Findings in Ulcerative Colitis Treatment --- p.28 / Chapter 1.4 --- Lactococcus lactis --- p.29 / Chapter 1.4.1 --- Overview --- p.29 / Chapter 1.4.2 --- Gene Expression System --- p.30 / Chapter 1.4.3 --- Nisin-Inducible Controlled Gene Expression (NICE) System --- p.31 / Chapter 1.4.4 --- Recent Studies of Treating Ulcerative Colitis with L. lactis and Recombinant L. lactis --- p.32 / Chapter 1.4.5 --- Safety Concern of the Use of Probiotics and Transgenic Probiotics --- p.33 / Chapter 1.5 --- Aims --- p.35 / Chapter Chapter 2 --- Material and Methodology --- p.36 / Chapter 2.1 --- General Materials --- p.36 / Chapter 2.1.1 --- Chemicals --- p.36 / Chapter 2.1.2 --- Antibodies and Commercial Kits --- p.41 / Chapter 2.1.3 --- Bacteria --- p.43 / Chapter 2.1.4 --- Animals --- p.43 / Chapter 2.1.5 --- Cell Lines --- p.44 / Chapter 2.1.5.1 --- Mouse Colonic Epithelial Cells --- p.44 / Chapter 2.1.5.2 --- Mouse Macrophages --- p.44 / Chapter 2.2 --- Experimental Designs --- p.45 / Chapter 2.2.1 --- Construction of mCRAMP-Encoding Lactococcus lactis --- p.45 / Chapter 2.2.1.1 --- Enumeration of L. lactis --- p.45 / Chapter 2.2.1.2 --- Bacteriostatic Effect of mCRAMP on L. lactis --- p.46 / Chapter 2.2.1.3 --- Construction of mCRAMP-Encoding L. lactis --- p.46 / Chapter 2.2.1.4 --- Detection of mCRAMP Production by Western Immunoblotting --- p.50 / Chapter 2.2.2 --- In vivo Studies --- p.52 / Chapter 2.2.2.1 --- Survival of mCRAMP-Encoding L. lactis in Murine Colon --- p.52 / Chapter 2.2.2.2 --- Toxicity of mCRAMP-Encoding L. lactis --- p.53 / Chapter 2.2.2.3 --- Determination of mCRAMP Expression in Colon Tissue --- p.53 / Chapter 2.2.2.4 --- Induction of Colitis --- p.54 / Chapter 2.2.2.5 --- Probiotic and Sulfasalazine Treatment --- p.54 / Chapter 2.2.2.6 --- Clinical Symptoms --- p.56 / Chapter 2.2.2.7 --- Morphological Analysis --- p.56 / Chapter 2.2.2.7.1 --- Haematoxylin-Eosin (H&E) Staining --- p.56 / Chapter 2.2.2.7.2 --- Periodic Acid-Schiff (PAS) Staining --- p.58 / Chapter 2.2.2.8 --- Assessment of Apoptosis and Proliferation by Immunohistochemistry --- p.60 / Chapter 2.2.2.8.1 --- Determination of Cell Apoptosis by Terminal Deoxynucleotidyl Transferase dUTP Nick-end Labeling --- p.60 / Chapter 2.2.2.8.2 --- Determination of Cell Proliferation by Proliferating Cell Nuclear Antigen (PCNA) Staining --- p.61 / Chapter 2.2.2.9 --- Determination of the Degree of Inflammation --- p.63 / Chapter 2.2.2.9.1 --- Colonic Myeloperoxidase (MPO) Activity --- p.63 / Chapter 2.2.2.9.2 --- Colonic Malondialdehyde (MDA) Level --- p.63 / Chapter 2.2.2.10 --- Fecal Microbiota Count --- p.64 / Chapter 2.2.2.11 --- mRNA Expression of Inflammatory Cytokines --- p.64 / Chapter 2.2.3 --- In vitro Studies --- p.66 / Chapter 2.2.3.1 --- Determination of Anti-inflammatory Effects of mCRAMP --- p.66 / Chapter 2.2.3.1.1 --- Cell Viability --- p.66 / Chapter 2.2.3.1.2 --- Determination of TNF-α Secretion under Stimulation of LTA and LPS --- p.66 / Chapter 2.2.3.1.3 --- Effects of mCRAMP on TNF-α Secretion Under Stimulation of LTA or LPS --- p.67 / Chapter 2.2.3.1.4 --- Effects of Pertussis Toxin (PTX) on the Inhibition of TNF-α Secretion by mCRAMP --- p.67 / Chapter 2.2.3.1.5 --- Nuclear Factor-κB (NF-κB) Luciferase Reporter Gene Assay in RAW 264.7 cells --- p.68 / Chapter 2.2.3.1.6 --- Determination of IκBα Expression and Phosphorylation by Western Immunoblotting --- p.69 / Chapter 2.2.3.1.7 --- Determination of Inducible Nitric Oxide Synthases (iNOS) and Cyclooxygenase-2 (COX-2) Expression by Western Immunoblotting --- p.70 / Chapter 2.2.3.2 --- Determination of Wound Healing Effects of mCRAMP --- p.72 / Chapter 2.2.3.2.1 --- Cell Viability --- p.72 / Chapter 2.2.3.2.2 --- Cell Migration --- p.74 / Chapter 2.2.3.2.3 --- Determination of Epidermal Growth Factor Receptor (EGFR), Extracellular Signal-Regulated Protein Kinase (ERK1/2) and p38 Expression and Phosphorylation by Western Immunoblotting --- p.76 / Chapter 2.3 --- Statistical Analysis --- p.76 / Chapter Chapter 3 --- Result --- p.77 / Chapter 3.1 --- Protective Effects of Cathelicidin-Encoding Lactococcus lactis in Murine Ulcerative Colitis --- p.77 / Chapter 3.1.1 --- Introduction --- p.77 / Chapter 3.1.2 --- Results --- p.79 / Chapter 3.1.2.1 --- Survival of mCRAMP-Encoding L. latis in Murine Colon --- p.79 / Chapter 3.1.2.2 --- Detection of mCRAMP-Encoded by L. lactis in vivo --- p.81 / Chapter 3.1.2.3 --- Toxicity of mCRAMP-Encoding L. lactis --- p.84 / Chapter 3.1.2.4 --- Clinical Symptoms --- p.86 / Chapter 3.1.2.5 --- Histology Evaluation --- p.89 / Chapter 3.1.2.6 --- Apoptosis --- p.93 / Chapter 3.1.2.7 --- Determination of mCRAMP Expression in Colon Tissue --- p.96 / Chapter 3.1.2.8 --- Determination of the Degree of Inflammation --- p.101 / Chapter 3.1.2.9 --- Faecal Microbiota Populations --- p.105 / Chapter 3.1.3 --- Discussion --- p.108 / Chapter 3.2 --- Therapeutic Effects of Cathelicidin-Encoding Lactococcus lactis in Murine Ulcerative Colitis --- p.113 / Chapter 3.2.1 --- Introduction --- p.113 / Chapter 3.2.2 --- Results --- p.115 / Chapter 3.2.2.1 --- Clinical Symptoms --- p.115 / Chapter 3.2.2.2 --- Histology Evaluation --- p.117 / Chapter 3.2.2.3 --- Cell Death and Proliferation in Colitis --- p.123 / Chapter 3.2.2.4 --- Determination of mCRAMP Expression in Colon Tissues --- p.127 / Chapter 3.2.2.5 --- Determination of the Degree of Inflammation --- p.130 / Chapter 3.2.2.6 --- Faecal Microbiota Populations --- p.133 / Chapter 3.2.3 --- Discussion --- p.135 / Chapter 3.3 --- Mechanistic Study of the Anti-inflammatory Effects of mCRAMP in Mouse Macrophages --- p.139 / Chapter 3.3.1 --- Introduction --- p.139 / Chapter 3.3.2 --- Results --- p.145 / Chapter 3.3.2.1 --- Viability of Macrophages --- p.145 / Chapter 3.3.2.2 --- Effects of LTA and LPS on Tumour Necrosis Factor-α (TNF-α) Release from Macrophages --- p.150 / Chapter 3.3.2.3 --- The Inhibition of TNF-α Secretion by mCRAMP --- p.153 / Chapter 3.3.2.4 --- Inhibition of TNF-α Secretion by mCRAMP Independent to GPCR Stimulation --- p.158 / Chapter 3.3.2.5 --- Activation of NF-κB Through Detection of Luciferase Activity --- p.163 / Chapter 3.3.2.6 --- Determination of the Expression and Phosphorylation of IκBα by Western Immunoblotting --- p.166 / Chapter 3.3.2.7 --- Determination of iNOS and COX-2 Expression by Western Immunoblotting --- p.169 / Chapter 3.3.2.8 --- The Suppression of iNOS and COX-2 Expression by mCRAMP was Independent to GPCR and P2X₇ Signalling --- p.183 / Chapter 3.3.3 --- Discussion --- p.188 / Chapter 3.4 --- Mechanistic Study on Wound Healing Effect of mCRAMP in Mouse Colon Epithelial Cells --- p.193 / Chapter 3.4.1 --- Introduction --- p.193 / Chapter 3.4.2 --- Results --- p.196 / Chapter 3.4.2.1 --- Cell Viability --- p.196 / Chapter 3.4.2.1.1 --- MTT Assay --- p.196 / Chapter 3.4.2.1.2 --- BrdU Incorporation --- p.200 / Chapter 3.4.2.2 --- Cell Migration --- p.202 / Chapter 3.4.2.3 --- Determination of Epidermal Growth Factor Receptor (EGFR), Extracellular Signal-Regulated Protein Kinase (ERK1/2) and p38 Expression and Phosphorylation by Western Immunoblotting --- p.210 / Chapter 3.4.3 --- Discussion --- p.215 / Chapter 4 Discussion and Future Perspectives --- p.219 / Publications --- p.224 / References --- p.227
|
12 |
Genetic investigation of inflammatory bowel disease and post-infectious irritable bowel syndrome : the contribution of innate immunity candidate risk variantsVillani, Alexandra-Chloé. January 2009 (has links)
The gastro-intestinal (GI) tract represents the largest surface of the body and is continuously exposed to the microbial environment. In such anatomy, the survival of the host requires that the intestinal microbial flora be contained without excessive immune-reactivity to commensal bacteria while retaining the ability to respond to episodic pathogens. The discriminative recognition between beneficial commensal bacteria and potentially harmful pathogens demands an accurate interpretation by the GI mucosal immune system. Any defects in the processes of innate immune recognition and killing may lead to the development and perpetuation of chronic intestinal inflammation, namely inflammatory bowel disease (i.e. Crohn's disease (CD) and ulcerative colitis (UC)) and post-infectious irritable bowel syndrome (PI-IBS). The aim of ours studies was to evaluate the contribution of candidate genes, involved in the homeostasis and regulation of the intestinal innate immune response, to the susceptibility to CD, DC, and PI-IBS. In the first phase, we describe functional and genetic association results supporting NLRP3, encoding NALP3/cryopyrin, as a novel CD susceptibility gene. We subsequently report that the MEFV gene, encoding pyrin, known to interact with and be involved in the same pathway as NALP3/cryopyrin, does not contribute to CD and DC susceptibility. No CD or DC additional associations were observed upon NLRP3-MEFV gene-gene interaction analyses. In the third phase, we report the first association study evaluating genetic determinants for PI-IBS, using the well-characterized Walkerton population cohort. We uncovered variants in the TLR9, CDH1, and IL6 regions associated with PI-IBS susceptibility. These results are in keeping with the pathophysiologic changes observed in patients with PI-IBS, which include increased intestinal permeability and intestinal immune activation. / Overall, these results contribute to a better understanding of the genetic susceptibility to CD, DC and PI-IBS and shed light on new pathogenic signaling pathways in the development of these diseases.
|
13 |
Nitric oxide in inflammatory bowel disease /Ljung, Tryggve, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.
|
14 |
Ulcerative colitis and cancer : with special reference to the increased colorectal cancer risk /Karlén, Per, January 1900 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 5 uppsatser.
|
15 |
Endoscopic methods for detecting malignancy in patients with ulcerative colitis and primary sclerosing cholangitis /Lindberg, Bo, January 2002 (has links)
Diss. (sammanfattning) Stockholm : Karol. Inst., 2002. / Härtill 4 uppsatser.
|
16 |
Genetic investigation of inflammatory bowel disease and post-infectious irritable bowel syndrome : the contribution of innate immunity candidate risk variantsVillani, Alexandra-Chloé. January 2009 (has links)
No description available.
|
17 |
"Estudo da microbiota intestinal em doentes com retocolite ulcerativa antes e após retocolectomia com anastomose de bolsa ileal ao canal anal" / Intestinal microbiota in patients with ulcerative colitis, before and after proctocolectomy and ileal pouch-anal anastomosisAlmeida, Maristela Gomes de 22 January 2004 (has links)
Este estudo tem como objetivo, descrever a microbiota intestinal de pacientes com retocolite ulcerativa grave, em tratamento clínico, antes e após retocolectomia com anastomose de bolsa ileal ao canal anal. Comparou-se a flora bacteriana do íleo terminal e do reto no pré-operatório com a flora encontrada na bolsa ileal após dois e oito meses do fechamento da ileostomia e com a flora do íleo terminal e do reto de um grupo controle. Observou-se que a Veillonella sp foi a bactéria mais freqüentemente encontrada em todos os grupos. Não houve diferenças significativas entre a flora intestinal do grupo controle e dos pacientes com retocolite ulcerativa / The aim of this study is to describe the intestinal microbiota of patients with severe ulcerative colitis, under clinical treatment, before and after proctocolectomy and ileal pouch-anal anastomosis. Intestinal flora of distal ileum and rectum before surgery was compared with the flora found in ileal pouch after two and eight months after ileostomy closure and with the flora of distal ileum and rectum of controls. Veillonella sp was the most frequent microorganism found in all groups. There were no significant differences between the intestinal microbiota found in controls and in patients with ulcerative colitis
|
18 |
Malignant transformation of the colorectal mucosa in inflammatory bowel disease /Sjöqvist, Urban, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.
|
19 |
Nitric oxide : a surrogate marker of bowel inflammation /Reinders, Claudia I., January 2005 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 4 uppsatser.
|
20 |
Nitric oxide and evaluation of different treatments in experimental colitis and inflammatory bowel disease /Lundberg, Sofie, January 2006 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 4 uppsatser.
|
Page generated in 0.0713 seconds